Investing in Brain-Computer Interfaces: What Every Investor Needs to Know
- Neuroba
- Jun 26
- 16 min read
Brain-computer interfaces are no longer a futuristic research concept. They are a capital market. More than $3.89 billion has flowed into BCI companies over the past decade. The most amount of funding was in 2025 at more than $1.15 billion, and 2026 has already seen a 799.73% rise in BCI funding compared to the same period in 2025. OpenAI led a $252 million round into a BCI startup. Neuralink is reportedly preparing a confidential IPO filing. NVIDIA has embedded itself as infrastructure for the category.
This is not a science project. This is a capital formation cycle, and investors who understand the structure of the market, the viable access routes, the revenue models, and the real risks will be positioned very differently from those who do not.
This guide is written for that investor: institutional, family office, or sophisticated individual, approaching BCIs with rigorous financial intent rather than headline enthusiasm.
What Is a Brain-Computer Interface Investment?
A brain-computer interface investment is exposure to any company in the technology stack that converts neural signals into digital commands or delivers therapeutic electrical stimulation to the nervous system.
The investment universe is broader than most investors realize. It spans five distinct layers:
Layer 1: Pure-play clinical BCI companies. These are the companies developing and implanting BCI devices in clinical trials - Neuralink, Synchron, Precision Neuroscience, Blackrock Neurotech, Paradromics. All are currently private. Their investability is limited to accredited investors through venture capital funds, secondary markets, or direct investment rounds.
Layer 2: Established neuromodulation companies. Medtronic (NYSE: MDT), Abbott Laboratories (NYSE: ABT), and Boston Scientific (NYSE: BSX) are publicly traded and generate billions in annual revenue from deep brain stimulation and spinal cord stimulation devices. They represent the proof case that neural interface therapy can scale commercially.
Layer 3: Enabling technology companies. NVIDIA (NASDAQ: NVDA), whose Holoscan platform is the AI edge computing layer being adopted by Synchron and Merge Labs; Butterfly Network (NYSE: BFLY), whose ultrasound-on-chip technology is licensed into Forest Neurotech; semiconductor manufacturers supplying the custom chips in implantable processors.
Layer 4: Small-cap and specialty public companies. NeuroPace (NASDAQ: NPCE), which makes the FDA-approved RNS System for epilepsy, and CeriBell (NASDAQ: CBLL), which received multiple FDA clearances in 2025 for its AI-powered point-of-care EEG system, are publicly traded BCI-adjacent plays.
Layer 5: Non-invasive consumer neurotechnology. Emotiv, OpenBCI, Kernel, and consumer EEG device companies targeting gaming, wellness, and productivity markets. Most are private; some consumer-facing technology companies with BCI product lines are publicly traded.
Understanding which layer you are investing in is the first discipline of BCI investing. The risk profile, time horizon, and expected return structure differ significantly across layers.
For a detailed overview of the companies building across these layers, see The 20 Most Important Brain-Computer Interface Companies Right Now.
The Investment Thesis: Why BCI, Why Now
The investment case for BCIs is not about hype. It is about a technology sitting at a specific inflection point - moving from demonstrated clinical proof to commercial deployment - at which historically outsized returns have been generated in comparable medical technology markets.
Thesis pillar 1: The regulatory inflection is arriving. Neuralink holds three FDA Breakthrough Device designations covering motor restoration, visual prosthetics, and speech restoration. Synchron has 12-month positive human trial data from its U.S. COMMAND study. Paradromics received FDA approval for its Connect-One Clinical Study with the Connexus BCI device in November 2025. FDA Breakthrough Device designation reduces time-to-market from 7 to 10 years to 4 to 6 years. The first PMA approval for a therapeutic communication BCI is widely expected within the 2026 to 2030 window. When it arrives, it triggers third-party payer reimbursement negotiations that transform BCI from a trial product into a billable clinical service.
Thesis pillar 2: The addressable patient population is large and non-discretionary. Bloomberg data showed U.S. BCI funding touched $2.75 billion, while China's sector surpassed 1.8 billion yuan in 2025. The patient populations driving this: 30,000 Americans with ALS at any given time, 17,000 new spinal cord injuries per year in the U.S. alone, 11.77 million Parkinson's patients globally. These are not discretionary purchases. They are patients for whom no pharmaceutical alternative provides comparable functional restoration.
Thesis pillar 3: The revenue model has multiple high-margin layers. Implantable BCIs can command $50,000 to $200,000 per device plus recurring software licensing fees. SaaS platforms are emerging as recurring revenue opportunities. Cognitive monitoring applications, projected to reach $150 million by 2026 at 17% growth, target corporate wellness programs and performance optimization. The AI decoding layer compounds in value with every additional patient in the dataset.
Thesis pillar 4: Comparable technology categories show the return potential. The cochlear implant market went from first FDA approval in 1984 to a global installed base of 700,000 patients by the early 2020s. Companies with early positions in cochlear implant technology generated returns that compressed dramatically after the market matured. The DBS market followed the same pattern. BCI is in the pre-approval phase that preceded both of those market formations.
Thesis pillar 5: The Neuralink IPO is a defined catalyst. The Neuralink IPO, when it comes, will be one of the most closely covered market events in neurotechnology history. Secondary market positioning before that event, and sector-wide readthrough effects on publicly traded BCI-adjacent names when it files, represent a defined catalyst timeline investors can plan around.
For context on where BCI clinical development stands today, see Brain Computer Interfaces in 2026: The Year Everything Changed.
How to Invest in BCIs Right Now: The Complete Access Map
The fundamental challenge of BCI investing in 2026 is that the most compelling pure-play companies are private. Here is the complete access map, structured by investor type and time horizon.
Route 1: Venture Capital Funds
The primary access route for institutional investors and qualified purchasers is through venture capital funds with dedicated neurotechnology or deep tech mandates.
VC Firm | Known BCI Investment Activity |
Lux Capital | Led Synchron's $75M Series C (2023), additional 2025 participation |
Khosla Ventures | Paradromics $33M round (2024); Science Corporation Series C lead |
Founders Fund | Early Neuralink; Precision Neuroscience $93M Series C (2024) |
ARCH Venture Partners | Science Corporation $160M round (2023), visual cortex focus |
Earlybird Venture Capital | Inbrain Neuroelectronics $50M Series B (2024), European focus |
Coatue Management | Consumer neurotechnology growth-stage deals (2025) |
8VC | Neural recording and stimulation portfolio companies |
Catalio Capital Management | Clinical-stage BCI companies (2025) |
SOSV / HAX | Early-stage hardware BCI companies (2025 to 2026) |
The most sophisticated institutional approach is LP positions in one or more of these funds, providing diversified exposure across the BCI venture portfolio rather than single-company concentration.
Route 2: Public Equities - Established Neuromodulation
For investors who require publicly traded liquidity, the largest and most defensible BCI exposure currently comes through established neuromodulation companies whose DBS divisions generate hundreds of millions in annual revenue.
Company and Ticker | BCI Relevance | Investment Profile |
Medtronic (NYSE: MDT) | World's largest DBS manufacturer; Percept PC with BrainSense AI | Large-cap, dividend-paying; BCI is optionality on core business |
Abbott Laboratories (NYSE: ABT) | Deep brain stimulation and neuromodulation division | Diversified medtech; lower BCI concentration than MDT |
Boston Scientific (NYSE: BSX) | DBS and neuromodulation products | Established clinical revenue; similar profile to Abbott |
NeuroPace (NASDAQ: NPCE) | FDA-approved RNS closed-loop epilepsy BCI; next-gen platform in FDA review | Small-cap pure-play; highest direct BCI revenue exposure in public markets |
CeriBell (NASDAQ: CBLL) | Multiple 2025 FDA clearances for AI-powered point-of-care EEG | Small-cap; recent IPO; non-invasive BCI diagnostics |
NeuroPace deserves specific attention. It is the only pure-play commercial BCI company currently publicly traded in the United States, manufacturing the RNS neurostimulator - a closed-loop brain-computer interface that detects epileptic activity and delivers responsive stimulation to prevent seizures. The company submitted its next-generation patient data platform for FDA review targeting approval in the second half of 2026.
Route 3: Public Equities - Enabling Technology
NVIDIA's Holoscan platform is the AI edge computing infrastructure being adopted by multiple leading BCI companies including Synchron, with Merge Labs also expected to train models on NVIDIA chips. Regardless of which BCI platform wins the clinical market, NVIDIA sits upstream. This is the clearest picks-and-shovels argument in the BCI investment universe.
Butterfly Network (NYSE: BFLY) is a more targeted enabling technology play. In Q4 2025, Butterfly reported revenue of $31.5 million, up 41% year-over-year, achieving its first quarter of positive operating cash flow. Full-year 2026 revenue guidance implies 20 to 24% growth. Butterfly's ultrasound-on-chip technology is licensed into Forest Neurotech, an Eric Schmidt-backed BCI research organization. The visible business generates real and accelerating revenue; the BCI optionality is additive.
Route 4: Secondary Markets and Pre-IPO
Accredited investors can access pre-IPO stakes in Neuralink, Synchron, and other leading private BCI companies through secondary market platforms including Forge Global, EquityZen, and Linqto. Neuralink is reportedly working toward a confidential IPO filing. The first BCI company to file an S-1 will be the single largest catalyst for the entire sector, moving every public name in the space within days.
Merge Labs represents a particularly notable pre-IPO position. Co-founded by Sam Altman in 2025 and emerging from stealth in January 2026 with $252 million in funding led by OpenAI at an $850 million valuation, Merge Labs is pursuing non-invasive ultrasound-based BCI rather than implants - a regulatory pathway distinction that could compress its commercialization timeline relative to surgical competitors.
For a full competitive analysis of these companies, see Best Brain-Computer Interfaces in 2026: Ranked and Reviewed.
BCI Revenue Models: What Investors Are Actually Buying
Understanding how BCI companies will generate revenue is essential to evaluating long-term investment quality. The sector has multiple revenue model architectures with very different margin and scalability profiles.
Revenue Model | Margin Profile | Companies Pursuing |
Device sale per implant ($50K to $200K) | High gross margin if manufacturing scales | Neuralink, Synchron, Precision Neuroscience |
Recurring AI software license (SaaS) | Very high margin, compounds with users | Synchron (Chiral), Neuralink |
Reimbursed clinical procedure (CPT codes) | Predictable, volume-driven post-approval | All post-approval clinical BCI companies |
Neural data licensing and research partnerships | High margin, low volume initially | Secondary revenue for all implant companies |
Consumer device sales (EEG, wearables) | Lower margin, high volume potential | Emotiv, OpenBCI, Kernel, NeuroSky |
Government and defense contracts | Premium pricing, long-term contract stability | Multiple research and device companies |
Enterprise cognitive monitoring (B2B SaaS) | Recurring, high retention | Kernel, emerging players |
The highest-quality long-term business model is the combination of per-implant device revenue plus recurring AI software platform subscription. This mirrors the razor-and-blade model that has driven durable value in medical device companies like Intuitive Surgical (NASDAQ: ISRG), whose da Vinci robot generated $8.4 billion in revenue in 2024 through capital equipment sales plus high-margin recurring consumables and software.
The Funding Landscape: Stage-by-Stage Capital Structure
Over the last decade, the BCI sector received $170 million in seed stage funding, $1.24 billion in early stage funding, and $2.28 billion in late stage funding. Total ten-year sector investment exceeded $3.89 billion. U.S. companies received $3.32 billion of that total - 85% of global BCI investment.
Year | BCI Sector Funding | Key Rounds |
2023 | $400M+ | Science Corporation $160M, Synchron $75M Series C |
2024 | $700M+ | Blackrock Neurotech $200M, Precision Neuroscience $102M |
2025 | $1.15B (record) | Neuralink $600M Series D, Synchron $200M Series D |
2026 (partial to mid-year) | $523M+ | Neuralink $650M Series E, CoMind EU87.8M |
The preponderance of late-stage capital - $2.28 billion of $3.89 billion total - signals the sector's leading companies have moved past seed and Series A validation into growth capital deployment. That is a materially different risk environment: company survival risk has decreased, but next-milestone risk (regulatory approval, reimbursement, clinical scaling) remains substantial.
The IPO Pipeline: The Catalyst Every Investor Must Track
Neuralink is the headline event. $9.6 billion private valuation as of May 2025. Reports of confidential IPO filing preparation throughout 2025 and 2026. The company plans to scale to 20,000 implants per year by 2031, implying a manufacturing and commercialization buildout that typically precedes or accompanies an IPO. Watch for S-1 filing as the primary catalyst signal.
Synchron is the most clinically de-risked candidate for early IPO. Twelve-month positive COMMAND trial data, U.S. patient base, Apple and Amazon platform integrations, and NVIDIA partnership create a story with real clinical evidence and platform-level distribution.
Precision Neuroscience has $155 million in total funding and intraoperative recording data from over 50 human patients. A pivotal clinical trial leading to PMA application would likely precede an IPO.
CeriBell (NASDAQ: CBLL) completed its IPO in 2024 and provides a current benchmark for how public markets have valued a BCI-adjacent diagnostics company with FDA-cleared products and meaningful hospital contracts.
BCI companies are beginning to demonstrate meaningful returns through strategic acquisitions and secondary sales. The 2026 to 2028 IPO window is open.
For Neuroba's forward view on BCI technology trajectory, see The Future of BCI Technology: 10 Predictions for the Next Decade.
Investment Risk Assessment: The Complete Picture
A credible investment thesis requires an equally credible risk analysis. BCI investing carries several category-specific risks that do not apply to most technology sectors.
Risk Category | Severity and Description | Mitigation Approach |
Regulatory delay | High - FDA PMA approval beyond expected timeline | Breakthrough Device designation partially mitigates; diversify across companies |
Electrode signal degradation | High - glial scarring reduces signal quality over years | Monitor trial longevity data; favor companies with multi-year implant stability evidence |
Reimbursement failure | Very High - CMS may not establish adequate payment codes post-approval | Cannot be mitigated by company selection; systemic sector risk |
Non-invasive disruption | Medium - superior non-invasive BCI obsoletes implant approach | Diversify across invasive and non-invasive exposure |
Manufacturing cost | Medium - per-implant cost remains too high for broad adoption | Monitor per-unit cost trajectory in company disclosures |
Neurorights regulation | Medium - data privacy laws add compliance cost and slow deployment | Track legislation in California, EU, and key markets |
Founder concentration | Medium - Musk's other obligations affect Neuralink sentiment | Neuralink management team is operationally independent |
IPO valuation risk | Medium - private valuations may not be validated by public markets | Secondary market analysis; public comparable benchmarking |
The most underappreciated risk in BCI investing is reimbursement. A BCI device can receive FDA approval and still fail commercially if CMS and private insurers do not establish reimbursement codes that make it economically viable for hospitals to implant. Cochlear implants and DBS both navigated complex reimbursement establishment processes after approval. BCI companies with the strongest reimbursement positioning will be those demonstrating clinical cost savings - reduced hospitalization, reduced caregiver burden, reduced long-term care costs - relative to device implant cost.
The AI Layer: The Investment Variable Nobody Is Fully Pricing
The standard financial analysis of BCI companies focuses on device revenue, regulatory timelines, and addressable patient populations. The variable most investors are underweighting is the AI neural decoding layer, which has the characteristics of a compounding data asset rather than a device business.
A UCLA neuroscience study published in November 2025 demonstrated that integrating an AI copilot significantly enhances BCI performance by filtering neural noise, predicting user intent, and improving control precision - reducing training time and enhancing real-world usability. The financial implication is structural: companies combining implanted BCI hardware with proprietary AI decoding models trained on longitudinal patient data are building a data moat with fundamentally different economics from device companies.
Synchron's Chiral cognitive foundation model, announced in March 2025, is the first explicit signal that a major BCI company understands this. The valuation premium that should accrue to a company with a proprietary neural foundation model versus a device-only BCI company is not yet being priced into the private market.
For investors conducting due diligence, the relevant questions are: Who owns the neural data generated by the device? What is the architecture for training and improving the AI decoder over time? Does the model transfer learning capability across patients? The answers will increasingly determine long-term enterprise value.
For Neuroba's analysis of this convergence, see The Future of Brain-Computer Interfaces: AI and Quantum Tech Leading the Way.
Building a BCI Investment Portfolio: A Tiered Framework
Tier 1: Core public market exposure (lower risk, liquid) Medtronic and Abbott provide dividend-paying, liquid neuromodulation exposure with established DBS revenue. NeuroPace provides a small-cap pure-play BCI position with FDA-approved product revenue. NVIDIA provides upstream infrastructure exposure. These positions can be sized according to standard portfolio allocation principles with full liquidity.
Tier 2: Enabling technology optionality (medium risk) Butterfly Network (BFLY) provides a company with real and growing revenue, positive operating cash flow trajectory, and meaningful BCI optionality through ultrasound-on-chip licensing to neurotechnology partners. The BCI exposure provides asymmetric upside if ultrasound-based non-invasive BCI achieves clinical validation.
Tier 3: Private venture fund exposure (higher risk, illiquid, highest potential return) For qualified purchasers and institutional investors, allocation to venture funds with documented BCI portfolio activity provides exposure to the pre-IPO value creation phase where the largest returns in medical device categories have historically been generated. Lux Capital, Khosla Ventures, and ARCH Venture Partners have the most established BCI portfolios.
Tier 4: IPO catalyst positioning (event-driven) As the Neuralink S-1 and potential Synchron or Precision Neuroscience IPO timelines approach, positioning in publicly traded BCI-adjacent names that will receive positive readthrough - NeuroPace, CeriBell, NVIDIA, Butterfly Network - represents a defined catalyst play with manageable downside.
Position sizing principle: BCI is a high-conviction, long-duration thesis with binary regulatory milestone risk. Position sizing should reflect both the asymmetric return potential and the genuine probability of regulatory or reimbursement failure at the company level. Diversification across investment layers reduces single-company milestone risk while maintaining meaningful sector exposure.
For a breakdown of what clinical applications are actually generating measurable outcomes today, see 15 Real-World Applications of Brain-Computer Interfaces Changing Lives Today.
The Geopolitical Dimension: China, Defense, and the Race for Neural Dominance
China's BCI sector surpassed 1.8 billion yuan in 2025. In June 2025, China launched its first clinical trial for an invasive BCI using a high-throughput wireless system implanted in a patient with tetraplegia. China's BCI investment has shifted from academic research support to clinical-stage development in a manner that has direct analogues in semiconductor and electric vehicle development timelines.
The defense dimension is explicit in U.S. government investment. DARPA's Neural Engineering System Design (NESD) and Next-Generation Nonsurgical Neurotechnology (N3) programs - the latter explicitly targeting non-invasive military BCIs for combat applications - represent the government's recognition that BCI is a strategically relevant technology rather than solely a medical one. Defense procurement contracts command premium pricing and long-term revenue stability.
The geopolitical competition creates a policy environment favorable to U.S. BCI sector investment. Companies that demonstrate dual-use clinical and defense applications, and that establish intellectual property positions preventing foreign replication, have a strategic case for U.S. government investment support beyond pure research grants.
For technical grounding on what these devices actually do, see Invasive Brain-Computer Interfaces: The Science Behind Brain Implants and The Core Technologies Powering Today's Brain-Computer Interfaces.
Frequently Asked Questions: BCI Investment
Is brain-computer interface a good investment?
BCI presents a high-conviction, long-duration investment case anchored in a large and growing neurological disease burden, imminent regulatory approvals, record-breaking VC momentum, and structural analogs in cochlear implants and DBS that generated substantial returns for early investors. The risks are real: regulatory timelines, reimbursement uncertainty, and manufacturing cost. The risk-adjusted case is strongest for investors who diversify across access routes and maintain a five to ten year time horizon.
Can retail investors invest in Neuralink?
Neuralink remains a private company as of mid-2026. Retail investors cannot directly purchase Neuralink equity. Accredited investors can access pre-IPO positions through secondary platforms such as Forge Global and EquityZen. Non-accredited retail investors can gain indirect exposure through publicly traded companies that benefit from BCI sector growth: NeuroPace (NPCE), NVIDIA (NVDA), Butterfly Network (BFLY), Medtronic (MDT), and Abbott (ABT).
When will Neuralink IPO?
Neuralink has not announced a confirmed IPO date as of mid-2026. Reports of confidential filing preparation circulated through 2025 and into 2026. The company's $9.6 billion valuation from its May 2025 Series D and $650 million April 2026 Series E suggest it is building the financial profile typical of a pre-IPO company. The IPO is widely expected in the 2026 to 2028 window, contingent on trial enrollment progress and regulatory milestone achievement.
What publicly traded stocks have BCI exposure?
The most direct publicly traded BCI exposure comes through NeuroPace (NASDAQ: NPCE), the only pure-play commercial BCI company currently listed in the United States. Additional exposure: Medtronic (NYSE: MDT) and Abbott (NYSE: ABT) for DBS divisions, CeriBell (NASDAQ: CBLL) for AI-powered EEG, Butterfly Network (NYSE: BFLY) for ultrasound technology licensed to BCI researchers, and NVIDIA (NASDAQ: NVDA) as AI infrastructure for BCI systems.
How much has been invested in BCI companies?
Over $3.89 billion has flowed into BCI companies over the past decade, with $1.15 billion raised in 2025 - the highest single-year total in sector history. The 2026 year-to-date figure of $523 million as of early 2026 represented a 799% increase over the same period in 2025, driven primarily by Neuralink's $650 million Series E. U.S. companies received 85% of total ten-year sector investment.
What is the expected return timeline for BCI investments?
BCI is a long-duration investment category. The most likely return timeline for private company positions is seven to twelve years from investment to liquidity event, consistent with novel medical device development and approval timelines. Investors in public neuromodulation companies receive current income through dividends plus long-term appreciation. The highest return potential - and highest risk - is in late-stage private positions that will IPO as clinical approvals arrive.
What is the biggest risk in BCI investing?
The most consequential risk is reimbursement. A BCI device can achieve FDA approval and still fail commercially if CMS and private insurers do not establish adequate reimbursement codes. This risk is sector-wide and cannot be mitigated through company selection. Secondary risks include long-term electrode signal stability in implanted devices, regulatory approval timeline uncertainty, and the potential for non-invasive BCI technology to reduce the addressable patient population for higher-risk invasive systems.
Which BCI companies have the best institutional backing?
Neuralink (Founders Fund, Bezos Expeditions), Synchron (Lux Capital, NVIDIA partnership), Precision Neuroscience (Founders Fund, institutional investors), Science Corporation (ARCH Venture Partners, Khosla Ventures), and Paradromics (Khosla Ventures, NIH, DARPA) represent companies with the strongest institutional backing. HHS is the single largest investor by number of companies funded across the BCI sector through research grant programs.
Key Takeaways
BCI is a capital market: over $3.89 billion invested across the past decade, $1.15 billion in 2025 alone, and a 799% year-over-year funding increase in early 2026.
The BCI investment universe spans five layers: pure-play private clinical companies, established public neuromodulation, enabling technology, small-cap public plays, and consumer neurotechnology.
Retail investors cannot directly access Neuralink equity but can gain BCI exposure through NeuroPace (NPCE), Medtronic (MDT), Abbott (ABT), NVIDIA (NVDA), and Butterfly Network (BFLY).
The Neuralink IPO, when it files, will be the single largest catalyst event for the publicly traded BCI-adjacent sector.
Implantable BCIs can command $50,000 to $200,000 per device plus recurring AI software licensing, creating a razor-and-blade revenue model with high long-term margins.
FDA Breakthrough Device designation reduces BCI approval timelines from 7 to 10 years to 4 to 6 years. Neuralink holds three such designations.
The AI neural decoding layer is the most underpriced long-term value creator in BCI companies - it compounds with every patient in the dataset in a way device hardware cannot.
The most consequential unmitigated risk is reimbursement: FDA approval does not guarantee commercial viability if CMS does not establish adequate payment codes.
China invested 1.8 billion yuan in BCI in 2025 and launched its first invasive BCI clinical trial in June 2025, creating geopolitical competition dynamics favorable to U.S. policy support.
A diversified BCI portfolio combines liquid public positions in neuromodulation and enabling technology with private fund exposure and pre-IPO secondary market positioning.
References
Tracxn. Brain Computer Interface: 2026 Market and Investments Trends. April 2026. https://tracxn.com/d/sectors/brain-computer-interface
MarketWise. Brain-Computer Interface Stocks: 14 Supply Chain Plays Before the Neuralink IPO. April 2026. https://marketwise.com/investing/brain-computer-interface-stocks-neuralink-ipo-supply-chain/
Insider Monkey. 10 Best Brain-Computer Interface Stocks to Buy. June 2026. https://www.insidermonkey.com/blog/10-best-brain-computer-interface-stocks-to-buy-1788676/
InvestorPlace. Brain Computer Interface Stocks: 10 Plays Beyond Neuralink. April 2026. https://investorplace.com/dailylive/2026/04/forget-neuralink-the-real-brain-tech-trade-has-10-names-youve-never-heard/
Ellty. Brain-Computer Interface Investors: 15 Active VCs in 2026. December 2025. https://www.ellty.com/blog/brain-computer-interface-investors
Quick Market Pitch. Neural Implants Top Investment Opportunities. July 2025. https://quickmarketpitch.com/blogs/news/brain-computer-interfaces-investment-opportunities
BCI Intel. State of BCI: 2026 Annual Industry Report. April 2026. https://bciintel.com/state-of-bci-2026/
Grand View Research. Brain Computer Interface Market Size. December 2025. https://www.grandviewresearch.com/industry-analysis/brain-computer-interfaces-market
Precedence Research. Brain Computer Interface Market Size to Hit USD 13.86 Billion by 2035. January 2026. https://www.precedenceresearch.com/brain-computer-interface-market
Sacra. Neuralink valuation, funding and news. April 2026. https://sacra.com/c/neuralink/
Medical Device Network. Neuralink wins FDA breakthrough tag for speech restoration. May 2025. https://www.medicaldevice-network.com/news/neuralink-wins-fda-breakthrough-tag-for-speech-restoration/
MedTech Dive. Synchron raises $200M to prepare for brain computer interface launch. November 2025. https://www.medtechdive.com/news/synchron-funding-bci-200m/804977/
Neuro Founders. The Big 6 of BCI: Where Neurotech Funding Is Flowing. November 2025. https://www.neurofounders.co/post/the-big-6-of-bci-where-neurotech-funding-is-flowing
Business Wire. Paradromics Receives FDA Approval for Connect-One Clinical Study. November 2025. https://www.businesswire.com
Fortune Business Insights. Brain Computer Interface Market Size Share and Growth. 2026. https://www.fortunebusinessinsights.com/brain-computer-interface-market-105811
Toward Healthcare. Brain Computer Interface Market to Grow at 16.7% CAGR till 2035. May 2026. https://www.towardshealthcare.com/insights/brain-computer-interface-market
NIH BRAIN Initiative. https://www.nih.gov
DARPA Neural Engineering System Design and N3 Programs. https://www.darpa.mil